doi: 10.1161/CIRCULATIONAHA.125.074545 Summary Keywords cardiovascular outcomes, SGLT2 inhibitors, GLP-1 agonists, combination therapy, heart failure, renal outcomes Citation Aristizbal-Colorado D, Corredor-Rengifo D, Sierra-Castillo S, Lpez-Corredor C, Vernaza-Trujillo D-A, Weir-Restrepo D, Izquierdo-Condoy JS, Ortiz-Prado E, Rico-Fontalvo J, Gmez-Mesa J-E, Abreu-Lomba A and Rivera-Martnez W-A (2025) A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists a comprehensive review
Most injectable GLP-1s are given once per week, while liraglutide is given once per day
Numerous other trials have demonstrated positive cardiovascular outcomes with focus on HFpEF in the SUMMIT trial for tirzepatide and the STEP-HFpEF trial for semaglutide [50,51,52]
Q6: Do I still need to diet and exercise while taking GLP-1s
Williams, who has always been a story unto herself, returns to the arena she dominated as a character in a larger debate hanging over the world of sports
Once approved, a managed transition would be possible under medical supervision